目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 37)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.3.3 CURRENCY CONSIDERED
1.4 RESEARCH LIMITATIONS
1.5 STAKEHOLDERS
1.6 RECESSION IMPACT

2 RESEARCH METHODOLOGY (Page No. - 41)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 ANTIBODY DRUG CONJUGATES MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 3 ANTIBODY DRUG CONJUGATES INDUSTRY: MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS (2022)
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS)
FIGURE 5 MARKET: REVENUE SHARE ANALYSIS OF F-HOFFMAN LA ROCHE LTD.
2.2.1 PRIMARY INSIGHTS
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
2.2.2 SEGMENT ASSESSMENT METHODOLOGY
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.3 GROWTH RATE ASSUMPTIONS
FIGURE 8 MARKET: CAGR PROJECTION ANALYSIS
FIGURE 9 MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 STUDY ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 RECESSION IMPACT ANALYSIS
TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2024-2028 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY (Page No. - 52)
FIGURE 11 ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 12 ANTIBODY DRUG CONJUGATES INDUSTRY, BY DISEASE TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 13 MARKET, BY LINKER TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 14 MARKET, BY TARGET TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 15 MARKET, BY PAYLOAD TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF MARKET

4 PREMIUM INSIGHTS (Page No. - 57)
4.1 ANTIBODY DRUG CONJUGATES MARKET OVERVIEW
FIGURE 17 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH DURING FORECAST PERIOD
4.2 NORTH AMERICA: ANTIBODY DRUG CONJUGATES INDUSTRY, BY DISEASE TYPE AND COUNTRY (2022)
FIGURE 18 BREAST CANCER SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
4.3 MARKET SHARE, BY PRODUCT, 2023 VS. 2028
FIGURE 19 KADCYLA SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.4 ANTIBODY DRUG CONJUGATES: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 20 ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH RATES FROM 2023 TO 2028

5 MARKET OVERVIEW (Page No. - 60)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 ANTIBODY DRUG CONJUGATES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 4 ANTIBODY DRUG CONJUGATES INDUSTRY: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence of cancer
TABLE 5 GLOBAL INCREASE IN NUMBER OF CANCER PATIENTS, 2015 VS. 2018 VS. 2035
5.2.1.2 Increasing investments for ADC development
5.2.1.3 Growing number of ADCs in clinical trials
TABLE 6 ASSET RANKING FOR LEADING ADC DEVELOPERS (2019 VS. 2023)
5.2.1.4 Favorable regulatory support
5.2.2 RESTRAINTS
5.2.2.1 High manufacturing costs
5.2.2.2 Side effects associated with ADCs
5.2.2.3 High attrition rate in product development
TABLE 7 LIST OF DISCONTINUED ANTIBODY DRUG CONJUGATES (2020−2022)
5.2.3 OPPORTUNITIES
5.2.3.1 Adoption of combination therapies
5.2.3.2 High growth in emerging economies
5.2.3.3 Emergence of advanced ADCs
5.2.4 CHALLENGES
5.2.4.1 Technical complexities
5.3 PIPELINE ANALYSIS
FIGURE 22 MARKET: CLINICAL TRIALS
5.4 VALUE CHAIN ANALYSIS
FIGURE 23 MARKET: VALUE CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.5.1 ROLE IN ECOSYSTEM
5.6 TECHNOLOGY ANALYSIS
TABLE 8 LEADING TECHNOLOGICAL ADVANCEMENTS FOR ADC GENERATIONS
5.7 REGULATORY ASSESSMENT
5.7.1 FDA REGULATIONS ON ANTIBODY DRUG CONJUGATES
5.7.1.1 CLINICAL PHARMACOLOGY CONSIDERATIONS
5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 14 MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 INTENSITY OF COMPETITIVE RIVALRY
5.8.2 BARGAINING POWER OF SUPPLIERS
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 THREAT OF SUBSTITUTES
5.8.5 THREAT OF NEW ENTRANTS
5.9 PATENT ANALYSIS
5.9.1 LIST OF MAJOR PATENTS
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 24 GROWING USE OF ACDS FOR ONCOLOGY AND OTHER CHRONIC DISEASES TO DRIVE MARKET
5.11 PRICING ANALYSIS
TABLE 15 MARKET: PRICING ANALYSIS OF ADC PRODUCTS, BY REGION
TABLE 16 MARKET: PRICING ANALYSIS OF ADC PRODUCTS, BY KEY PLAYERS
5.12 KEY CONFERENCES AND EVENTS
TABLE 17 MARKET: DETAILED LIST OF EVENTS AND CONFERENCES (2023−2024)
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
FIGURE 25 KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES AND INFLUENCE ON BUYING PROCESS
FIGURE 26 KEY BUYING CRITERIA FOR ADC PRODUCTS AMONG END USERS

6 ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT (Page No. - 89)
6.1 INTRODUCTION
TABLE 18 ANTIBODY DRUG CONJUGATES INDUSTRY, BY PRODUCT, 2021-2028 (USD MILLION)
6.2 KADCYLA
6.2.1 LAUNCH OF BIOSIMILARS TO DRIVE MARKET
TABLE 19 MARKET FOR KADCYLA, BY REGION, 2021-2028 (USD MILLION)
TABLE 20 NORTH AMERICA: MARKET FOR KADCYLA, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 21 EUROPE: MARKET FOR KADCYLA, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 22 ASIA PACIFIC: MARKET FOR KADCYLA, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 23 LATIN AMERICA: MARKET FOR KADCYLA, BY COUNTRY, 2021-2028 (USD MILLION)
6.3 ENHERTU
6.3.1 RISING INCIDENCE OF BREAST CANCER TO PROPEL MARKET
TABLE 24 MARKET FOR ENHERTU, BY REGION, 2021-2028 (USD MILLION)
TABLE 25 NORTH AMERICA: MARKET FOR ENHERTU, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 26 EUROPE: MARKET FOR ENHERTU, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 27 ASIA PACIFIC: MARKET FOR ENHERTU, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 28 LATIN AMERICA: MARKET FOR ENHERTU, BY COUNTRY, 2021-2028 (USD MILLION)
6.4 ADCETRIS
6.4.1 GROWING CASES OF HODGKIN LYMPHOMA TO DRIVE MARKET
TABLE 29 MARKET FOR ADCETRIS, BY REGION, 2021-2028 (USD MILLION)
TABLE 30 NORTH AMERICA: MARKET FOR ADCETRIS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 31 EUROPE: MARKET FOR ADCETRIS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 32 ASIA PACIFIC: MARKET FOR ADCETRIS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 33 LATIN AMERICA: MARKET FOR ADCETRIS, BY COUNTRY, 2021-2028 (USD MILLION)
6.5 PADCEV
6.5.1 RISING INCIDENCE OF UROTHELIAL CANCER TO DRIVE MARKET
TABLE 34 MARKET FOR PADCEV MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 35 NORTH AMERICA: MARKET FOR PADCEV, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 36 EUROPE: MARKET FOR PADCEV, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 37 ASIA PACIFIC: MARKET FOR PADCEV, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 38 LATIN AMERICA: MARKET FOR PADCEV, BY COUNTRY, 2021-2028 (USD MILLION)
6.6 TRODELVY
6.6.1 INCREASING GOVERNMENT APPROVALS FOR BREAST CANCER TO DRIVE MARKET
TABLE 39 MARKET FOR TRODELVY MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 40 NORTH AMERICA: MARKET FOR TRODELVY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 41 EUROPE: MARKET FOR TRODELVY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 42 ASIA PACIFIC: MARKET FOR TRODELVY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 43 LATIN AMERICA: MARKET FOR TRODELVY, BY COUNTRY, 2021-2028 (USD MILLION)
6.7 POLIVY
6.7.1 RISING PREVALENCE OF NON-HODGKIN LYMPHOMA TO PROPEL MARKET
TABLE 44 MARKET FOR POLIVY MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 45 NORTH AMERICA: MARKET FOR POLIVY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 46 EUROPE: MARKET FOR POLIVY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 47 ASIA PACIFIC: MARKET FOR POLIVY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 48 LATIN AMERICA: MARKET FOR POLIVY, BY COUNTRY, 2021-2028 (USD MILLION)
6.8 OTHER PRODUCTS
TABLE 49 MARKET FOR OTHER PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
TABLE 50 NORTH AMERICA: MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 51 EUROPE: MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 52 ASIA PACIFIC: MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 53 LATIN AMERICA: MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2021-2028 (USD MILLION)

7 ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE (Page No. - 109)
7.1 INTRODUCTION
TABLE 54 ANTIBODY DRUG CONJUGATES INDUSTRY, BY LINKER TYPE, 2021-2028 (USD MILLION)
7.2 CLEAVABLE LINKERS
7.2.1 HIGH COMPATIBILITY WITH BROAD RANGE OF DRUGS TO DRIVE MARKET
TABLE 55 MARKET FOR CLEAVABLE LINKERS, BY REGION, 2021-2028 (USD MILLION)
TABLE 56 NORTH AMERICA: MARKET FOR CLEAVABLE LINKERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 57 EUROPE: MARKET FOR CLEAVABLE LINKERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 58 ASIA PACIFIC: MARKET FOR CLEAVABLE LINKERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 59 LATIN AMERICA: MARKET FOR CLEAVABLE LINKERS, BY COUNTRY, 2021-2028 (USD MILLION)
7.3 NON-CLEAVABLE LINKERS
7.3.1 LOW TOXICITY LEVELS TO SUPPORT MARKET GROWTH
TABLE 60 MARKET FOR NON-CLEAVABLE LINKERS, BY REGION, 2021-2028 (USD MILLION)
TABLE 61 NORTH AMERICA: MARKET FOR NON-CLEAVABLE LINKERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 62 EUROPE: MARKET FOR NON-CLEAVABLE LINKERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 63 ASIA PACIFIC: MARKET FOR NON-CLEAVABLE LINKERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 64 LATIN AMERICA: MARKET FOR NON-CLEAVABLE LINKERS, BY COUNTRY, 2021-2028 (USD MILLION)

8 ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE (Page No. - 116)
8.1 INTRODUCTION
TABLE 65 ANTIBODY DRUG CONJUGATES INDUSTRY, BY TARGET TYPE, 2021-2028 (USD MILLION)
8.2 HER2
8.2.1 RISING PREVALENCE OF BREAST CANCER TO DRIVE MARKET
TABLE 66 MARKET FOR HER2, BY REGION, 2021-2028 (USD MILLION)
TABLE 67 NORTH AMERICA: MARKET FOR HER2, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 68 EUROPE: MARKET FOR HER2, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 69 ASIA PACIFIC: MARKET FOR HER2, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 70 LATIN AMERICA: MARKET FOR HER2, BY COUNTRY, 2021-2028 (USD MILLION)
8.3 CD22
8.3.1 INCREASING CASES OF B-CELL LYMPHOMAS TO DRIVE MARKET
TABLE 71 MARKET FOR CD22, BY REGION, 2021-2028 (USD MILLION)
TABLE 72 NORTH AMERICA: MARKET FOR CD22, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 73 EUROPE: MARKET FOR CD22, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 74 ASIA PACIFIC: MARKET FOR CD22, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 75 LATIN AMERICA: MARKET FOR CD22, BY COUNTRY, 2021-2028 (USD MILLION)
8.4 CD30
8.4.1 INCREASING CLINICAL TRIALS FOR PRODUCT LAUNCHES TO SUPPORT MARKET GROWTH
TABLE 76 MARKET FOR CD30, BY REGION, 2021-2028 (USD MILLION)
TABLE 77 NORTH AMERICA: MARKET FOR CD30, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 78 EUROPE: MARKET FOR CD30, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 79 ASIA PACIFIC: MARKET FOR CD30, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 80 LATIN AMERICA: MARKET FOR CD30, BY COUNTRY, 2021-2028 (USD MILLION)
8.5 OTHER TARGET TYPES
TABLE 81 MARKET FOR OTHER TARGET TYPES, BY REGION, 2021-2028 (USD MILLION)
TABLE 82 NORTH AMERICA: MARKET FOR OTHER TARGET TYPES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 83 EUROPE: MARKET FOR OTHER TARGET TYPES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 84 ASIA PACIFIC: MARKET FOR OTHER TARGET TYPES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 85 LATIN AMERICA: MARKET FOR OTHER TARGET TYPES, BY COUNTRY, 2021-2028 (USD MILLION)

9 ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE (Page No. - 127)
9.1 INTRODUCTION
TABLE 86 ANTIBODY DRUG CONJUGATES INDUSTRY, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
9.2 MONOMETHYL AURISTATIN E
9.2.1 CYTOTOXIC PAYLOAD FOR ADC DEVELOPMENT TO DRIVE MARKET
TABLE 87 MARKET FOR MONOMETHYL AURISTATIN E, BY REGION, 2021-2028 (USD MILLION)
TABLE 88 NORTH AMERICA: MARKET FOR MONOMETHYL AURISTATIN E, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 89 EUROPE: MARKET FOR MONOMETHYL AURISTATIN E, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 90 ASIA PACIFIC: MARKET FOR MONOMETHYL AURISTATIN E, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 91 LATIN AMERICA: MARKET FOR MONOMETHYL AURISTATIN E, BY COUNTRY, 2021-2028 (USD MILLION)
9.3 CALICHEAMICIN
9.3.1 LAUNCH OF CALICHEAMICIN-BASED ADCS TO PROPEL MARKET
TABLE 92 MARKET FOR CALICHEAMICIN, BY REGION, 2021-2028 (USD MILLION)
TABLE 93 NORTH AMERICA: MARKET FOR CALICHEAMICIN, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 94 EUROPE: MARKET FOR CALICHEAMICIN, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 95 ASIA PACIFIC: MARKET FOR CALICHEAMICIN, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 96 LATIN AMERICA: MARKET FOR CALICHEAMICIN, BY COUNTRY, 2021-2028 (USD MILLION)
9.4 MAYTANSINOIDS
9.4.1 INNOVATIVE PRODUCT PIPELINE TO SUPPORT MARKET GROWTH
TABLE 97 MARKET FOR MAYTANSINOIDS, BY REGION, 2021-2028 (USD MILLION)
TABLE 98 NORTH AMERICA: MARKET FOR MAYTANSINOIDS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 99 EUROPE: MARKET FOR MAYTANSINOIDS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 100 ASIA PACIFIC: MARKET FOR MAYTANSINOIDS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 101 LATIN AMERICA: MARKET FOR MAYTANSINOIDS, BY COUNTRY, 2021-2028 (USD MILLION)
9.5 OTHER PAYLOAD TYPES
TABLE 102 MARKET FOR OTHER PAYLOAD TYPES, BY REGION, 2021-2028 (USD MILLION)
TABLE 103 NORTH AMERICA: MARKET FOR OTHER PAYLOAD TYPES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 104 EUROPE: MARKET FOR OTHER PAYLOAD TYPES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 105 ASIA PACIFIC: MARKET FOR OTHER PAYLOAD TYPES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 106 LATIN AMERICA: MARKET FOR OTHER PAYLOAD TYPES, BY COUNTRY, 2021-2028 (USD MILLION)

10 ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE (Page No. - 138)
10.1 INTRODUCTION
TABLE 107 ANTIBODY DRUG CONJUGATES INDUSTRY, BY DISEASE TYPE, 2021-2028 (USD MILLION)
10.2 BREAST CANCER
10.2.1 RISING CASES OF INFLAMMATORY BREAST CANCER TO DRIVE MARKET
TABLE 108 PROJECTION OF BREAST CANCER RATES
TABLE 109 MARKET FOR BREAST CANCER, BY REGION, 2021-2028 (USD MILLION)
TABLE 110 NORTH AMERICA: MARKET FOR BREAST CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 111 EUROPE: MARKET FOR BREAST CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 112 ASIA PACIFIC: MARKET FOR BREAST CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 113 LATIN AMERICA: MARKET FOR BREAST CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
10.3 BLOOD CANCER
10.3.1 INCREASING FOCUS ON CLINICAL TRIALS FOR ADVANCED CONJUGATES TO PROPEL MARKET
TABLE 114 GLOBAL INCIDENCE OF BLOOD CANCER
TABLE 115 ESTIMATED NEW BLOOD CANCER CASES IN US (2023)
TABLE 116 MARKET FOR BLOOD CANCER, BY REGION, 2021-2028 (USD MILLION)
TABLE 117 NORTH AMERICA: MARKET FOR BLOOD CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 118 EUROPE: MARKET FOR BLOOD CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 119 ASIA PACIFIC: MARKET FOR BLOOD CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 120 LATIN AMERICA: MARKET FOR BLOOD CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
10.4 OTHER DISEASE TYPES
TABLE 121 MARKET FOR OTHER DISEASE TYPES, BY REGION, 2021-2028 (USD MILLION)
TABLE 122 NORTH AMERICA: MARKET FOR OTHER DISEASE TYPES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 123 EUROPE: MARKET FOR OTHER DISEASE TYPES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 124 ASIA PACIFIC: MARKET FOR OTHER DISEASE TYPES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 125 LATIN AMERICA: MARKET FOR OTHER DISEASE TYPES, BY COUNTRY, 2021-2028 (USD MILLION)

11 ANTIBODY DRUG CONJUGATES MARKET, BY REGION (Page No. - 148)
11.1 INTRODUCTION
TABLE 126 ANTIBODY DRUG CONJUGATES INDUSTRY, BY REGION, 2021-2028 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 27 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET SNAPSHOT
TABLE 127 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 128 NORTH AMERICA: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 129 NORTH AMERICA: MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
TABLE 130 NORTH AMERICA: MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
TABLE 131 NORTH AMERICA: MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
TABLE 132 NORTH AMERICA: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
11.2.1 US
11.2.1.1 Rising regulatory approvals for ADCs to drive market
TABLE 133 US: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 134 US: MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
TABLE 135 US: MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
TABLE 136 US: MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
TABLE 137 US: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
11.2.2 CANADA
11.2.2.1 High R&D investments for novel ADCs to propel market
TABLE 138 CANADA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 139 CANADA: MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
TABLE 140 CANADA: MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
TABLE 141 CANADA: MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
TABLE 142 CANADA: CONJUGATES MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
11.2.3 NORTH AMERICA: RECESSION IMPACT
11.3 EUROPE
TABLE 143 EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 144 EUROPE: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 145 EUROPE: MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
TABLE 146 EUROPE: MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
TABLE 147 EUROPE: MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
TABLE 148 EUROPE: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Increasing collaborations among market players for cancer therapeutics to propel market
TABLE 149 GERMANY: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 150 GERMANY: MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
TABLE 151 GERMANY: MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
TABLE 152 GERMANY: MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
TABLE 153 GERMANY: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
11.3.2 FRANCE
11.3.2.1 Growing demand for personalized therapeutics to drive market
TABLE 154 FRANCE: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 155 FRANCE: MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
TABLE 156 FRANCE: MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
TABLE 157 FRANCE: MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
TABLE 158 FRANCE: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
11.3.3 UK
11.3.3.1 Increasing cancer burden to support market growth
TABLE 159 UK: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 160 UK: MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
TABLE 161 UK: MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
TABLE 162 UK: MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
TABLE 163 UK: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
11.3.4 ITALY
11.3.4.1 Rising industrial collaborations for ADC production to drive market
TABLE 164 ITALY: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 165 ITALY: MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
TABLE 166 ITALY: MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
TABLE 167 ITALY: MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
TABLE 168 ITALY: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Rising focus on drug discovery to support market growth
TABLE 169 SPAIN: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 170 SPAIN: MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
TABLE 171 SPAIN: MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
TABLE 172 SPAIN: MARKET, BY TARGET, 2021-2028 (USD MILLION)
TABLE 173 SPAIN: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
11.3.6 REST OF EUROPE
TABLE 174 REST OF EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 175 REST OF EUROPE: MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
TABLE 176 REST OF EUROPE: MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
TABLE 177 REST OF EUROPE: MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
TABLE 178 REST OF EUROPE: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
11.3.7 EUROPE: RECESSION IMPACT
11.4 ASIA PACIFIC
FIGURE 28 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET SNAPSHOT
TABLE 179 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 180 ASIA PACIFIC: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 181 ASIA PACIFIC: MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
TABLE 182 ASIA PACIFIC: MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
TABLE 183 ASIA PACIFIC: MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
TABLE 184 ASIA PACIFIC: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
11.4.1 CHINA
11.4.1.1 Rising initiatives for advanced therapies to drive market
TABLE 185 CHINA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 186 CHINA: MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
TABLE 187 CHINA: MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
TABLE 188 CHINA: MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
TABLE 189 CHINA: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 Favorable regulatory support to propel market
TABLE 190 JAPAN: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 191 JAPAN: MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
TABLE 192 JAPAN: MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
TABLE 193 JAPAN: MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
TABLE 194 JAPAN: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Emergence of innovative biosimilars to drive market
TABLE 195 INDIA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 196 INDIA: MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
TABLE 197 INDIA: MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
TABLE 198 INDIA: MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
TABLE 199 INDIA: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
11.4.4 REST OF ASIA PACIFIC
TABLE 200 REST OF ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 201 REST OF ASIA PACIFIC: MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
TABLE 202 REST OF ASIA PACIFIC: MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
TABLE 203 REST OF ASIA PACIFIC: MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
TABLE 204 REST OF ASIA PACIFIC: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
11.4.5 ASIA PACIFIC: RECESSION IMPACT
11.5 LATIN AMERICA
TABLE 205 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 206 LATIN AMERICA: MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 207 LATIN AMERICA: MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
TABLE 208 LATIN AMERICA: MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
TABLE 209 LATIN AMERICA: MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
TABLE 210 LATIN AMERICA: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
11.5.1 BRAZIL
11.5.1.1 Regulatory approvals for breast cancer therapeutics to drive market
TABLE 211 BRAZIL: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 212 BRAZIL: MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
TABLE 213 BRAZIL: MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
TABLE 214 BRAZIL: MARKET, BY TARGET, 2021-2028 (USD MILLION)
TABLE 215 BRAZIL: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
11.5.2 REST OF LATIN AMERICA
TABLE 216 REST OF LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 217 REST OF LATIN AMERICA: MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
TABLE 218 REST OF LATIN AMERICA: MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
TABLE 219 REST OF LATIN AMERICA: MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
TABLE 220 REST OF LATIN AMERICA: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
11.5.3 LATIN AMERICA: RECESSION IMPACT
11.6 MIDDLE EAST & AFRICA
11.6.1 RISING PRODUCT LAUNCHES FOR CANCER THERAPEUTICS TO SUPPORT MARKET GROWTH
TABLE 221 MIDDLE EAST & AFRICA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 222 MIDDLE EAST & AFRICA: MARKET, BY LINKER TYPE, 2021-2028 (USD MILLION)
TABLE 223 MIDDLE EAST & AFRICA: MARKET, BY PAYLOAD TYPE, 2021-2028 (USD MILLION)
TABLE 224 MIDDLE EAST & AFRICA: MARKET, BY TARGET TYPE, 2021-2028 (USD MILLION)
TABLE 225 MIDDLE EAST & AFRICA: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
11.7 MIDDLE EAST & AFRICA: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE (Page No. - 202)
12.1 INTRODUCTION
12.2 STRATEGIES ADOPTED BY KEY PLAYERS
TABLE 226 ANTIBODY DRUG CONJUGATES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
12.3 REVENUE SHARE ANALYSIS
FIGURE 29 REVENUE SHARE ANALYSIS OF KEY PLAYERS (2019-2022)
12.4 MARKET SHARE ANALYSIS
FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
TABLE 227 ANTIBODY DRUG CONJUGATES INDUSTRY: INTENSITY OF COMPETITIVE RIVALRY
12.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS
FIGURE 31 ANTIBODY DRUG CONJUGATES INDUSTRY: COMPANY EVALUATION MATRIX (2022)
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.6 COMPETITIVE BENCHMARKING OF 25 PLAYERS
12.6.1 PRODUCT FOOTPRINT OF 11 COMPANIES
TABLE 228 ANTIBODY DRUG CONJUGATES INDUSTRY: COMPANY FOOTPRINT ANALYSIS OF KEY PLAYERS
TABLE 229 ANTIBODY DRUG CONJUGATES INDUSTRY: PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS
12.6.2 REGIONAL FOOTPRINT OF 26 COMPANIES
TABLE 230 ANTIBODY DRUG CONJUGATES INDUSTRY: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
12.7 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES
FIGURE 32 ANTIBODY DRUG CONJUGATES INDUSTRY: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
12.7.1 PROGRESSIVE COMPANIES
12.7.2 STARTING BLOCKS
12.7.3 RESPONSIVE COMPANIES
12.7.4 DYNAMIC COMPANIES
12.8 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
TABLE 231 ANTIBODY DRUG CONJUGATES INDUSTRY: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 232 ANTIBODY DRUG CONJUGATES INDUSTRY: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
12.9 COMPETITIVE SCENARIO AND TRENDS
12.9.1 PRODUCT LAUNCHES
TABLE 233 ANTIBODY DRUG CONJUGATES INDUSTRY: PRODUCT LAUNCHES (JANUARY 2020-JUNE 2023)
12.9.2 DEALS
TABLE 234 ANTIBODY DRUG CONJUGATES MARKET: DEALS (JANUARY 2020−JUNE 2023)

13 COMPANY PROFILES (Page No. - 219)
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
13.1 KEY PLAYERS
13.1.1 F. HOFFMANN-LA ROCHE LTD.
TABLE 235 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
FIGURE 33 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
13.1.2 DAIICHI SANKYO COMPANY, LIMITED
TABLE 236 DAIICHI SANKYO COMPANY, LIMITED: BUSINESS OVERVIEW
FIGURE 34 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2022)
13.1.3 SEAGEN INC.
TABLE 237 SEAGEN INC.: BUSINESS OVERVIEW
FIGURE 35 SEAGEN INC.: COMPANY SNAPSHOT (2022)
13.1.4 GILEAD SCIENCES, INC.
TABLE 238 GILEAD SCIENCES, INC.: BUSINESS OVERVIEW
FIGURE 36 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2022)
13.1.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED
TABLE 239 TAKEDA PHARMACEUTICAL COMPANY LIMITED: BUSINESS OVERVIEW
FIGURE 37 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)
13.1.6 PFIZER INC.
TABLE 240 PFIZER INC.: BUSINESS OVERVIEW
FIGURE 38 PFIZER INC.: COMPANY SNAPSHOT (2022)
13.1.7 ASTELLAS PHARMA INC.
TABLE 241 ASTELLAS PHARMA INC.: BUSINESS OVERVIEW
FIGURE 39 ASTELLAS PHARMA INC: COMPANY SNAPSHOT (2022)
13.1.8 ASTRAZENECA
TABLE 242 ASTRAZENECA: BUSINESS OVERVIEW
FIGURE 40 ASTRAZENECA: COMPANY SNAPSHOT (2022)
13.1.9 ADC THERAPEUTICS SA
TABLE 243 ADC THERAPEUTICS SA: BUSINESS OVERVIEW
FIGURE 41 ADC THERAPEUTICS SA: COMPANY SNAPSHOT (2022)
13.1.10 IMMUNOGEN, INC.
TABLE 244 IMMUNOGEN, INC.: BUSINESS OVERVIEW
FIGURE 42 IMMUNOGEN, INC.: COMPANY SNAPSHOT (2022)
13.1.11 ZYDUS GROUP
TABLE 245 ZYDUS GROUP: BUSINESS OVERVIEW
FIGURE 43 ZYDUS GROUP: COMPANY SNAPSHOT (2022)
13.2 OTHER PLAYERS
13.2.1 ABBVIE INC.
TABLE 246 ABBVIE INC.: BUSINESS OVERVIEW
13.2.2 AMBRX
TABLE 247 AMBRX: BUSINESS OVERVIEW
13.2.3 LEGOCHEM BIOSCIENCES, INC.
TABLE 248 LEGOCHEM BIOSCIENCES, INC.: BUSINESS OVERVIEW
13.2.4 BYONDIS
TABLE 249 BYONDIS: BUSINESS OVERVIEW
13.2.5 PROFOUNDBIO
TABLE 250 PROFOUNDBIO: BUSINESS OVERVIEW
13.2.6 REMEGEN
TABLE 251 REMEGEN: BUSINESS OVERVIEW
13.2.7 SUTRO BIOPHARMA, INC.
TABLE 252 SUTRO BIOPHARMA, INC.: BUSINESS OVERVIEW
13.2.8 LEPU BIOPHARMA CO., LTD.
TABLE 253 LEPU BIOPHARMA CO., LTD.: BUSINESS OVERVIEW
13.2.9 ZYMEWORKS INC.
TABLE 254 ZYMEWORKS INC.: BUSINESS OVERVIEW
13.2.10 MERSANA THERAPEUTICS
TABLE 255 MERSANA THERAPEUTICS: BUSINESS OVERVIEW
13.2.11 DUALITY BIOLOGICS
TABLE 256 DUALITY BIOLOGICS: BUSINESS OVERVIEW
13.2.12 LANOVA MEDICINES
TABLE 257 LANOVA MEDICINES: BUSINESS OVERVIEW
13.2.13 EXELIXIS, INC.
TABLE 258 EXELIXIS, INC.: BUSINESS OVERVIEW
13.2.14 BIONECURE THERAPEUTICS INC.
TABLE 259 BIONECURE THERAPEUTICS INC.: BUSINESS OVERVIEW
13.2.15 TRIPARTITE THERAPEUTICS, INC.
TABLE 260 TRIPARTITE THERAPEUTICS, INC.: BUSINESS OVERVIEW
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.

14 APPENDIX (Page No. - 275)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS